Clinical Trials Using Blinatumomab
Clinical trials are research studies that involve people. The clinical trials on this list are studying Blinatumomab. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma
Primary Objective: • To evaluate the safety and tolerability of subcutaneous (SC) blinatumomab dose administrations Secondary Objectives: - To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations - To estimate the maximum tolerated dose (MTD) tested for blinatumomab administered subcutaneously - To determine the incidence of anti-blinatumomab antibody formation following SC administration - To evaluate efficacy response following treatment with SC blinatumomab administration Exploratory Objective: - To determine the pharmacodynamics (PD) time profiles for B-and T-lymphocytes as well as cytokine profiles during SC administration - To evaluate efficacy response following treatment with SC blinatumomab administration using Lugano criteria if positron emission tomography-computed tomography (PET / CT) is used for evaluation
Location: See Clinical Trials.gov
Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to determine the safety and feasibility of outpatient blinatumomab administration for subjects with Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia.
Location: 2 locations
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
This phase II trial investigates how well nivolumab when given together with blinatumomab work compared to blinatumomab alone in treating patients with CD19+ B-cell acute lymphoblastic leukemia or Down syndrome that has come back (relapsed). Blinatumomab is an antibody, which is a protein that identifies and targets foreign substances in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs that kills the cancer cell. Nivolumab is a medicine that is used to boost a patient’s immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
Location: Location information is not yet available.